Stocks · News reference

Lexicon Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.

Aug 6, 2026, 12:46 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 6, 2026, 12:46 PM
Checked: Aug 6, 2026, 12:46 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 31, 2026, 12:32 PMBenzinga Newsdesk
Lexicon Pharmaceuticals Says Post Hoc Analysis Of Phase 3 SOLOIST-WHF Trial Shows Sotagliflozin Reduced Cardiovascular Deaths, Heart Failure Events Regardless Of Baseline Systolic Blood Pressure, Without Increase In Hypotension Or Acute Kidney Injury
LXRX
BenzingaAug 24, 2026, 12:31 PMBenzinga Newsdesk
Lexicon Pharmaceuticals Announces Third $10M Milestone Payment Of 2026 From Novo Nordisk On LX9851 Phase 1 Dosing Milestone
LXRX
BenzingaAug 6, 2026, 11:48 AMBenzinga Newsdesk
Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 800 percent decrease over earnings of $0.01 per share
LXRX